Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1986-11-3
|
pubmed:abstractText |
The in-vitro synergistic activity of YTR 830, a new beta-lactamase inhibitor, combined with four extended-spectrum penicillins (ticarcillin, piperacillin, mezlocillin and apalcillin) against ticarcillin-resistant clinical isolates of Gram-negative enteric bacilli was compared with that of clavulanate and sulbactam. Synergy testing was performed with fixed concentrations of beta-lactamase inhibitors (8 mg/l) combined with doubling dilutions of beta-lactams in microdilution trays. Synergy was defined as a four-fold or greater decrease of beta-lactam MIC in the combination compared with the beta-lactam alone. For 79 ticarcillin-resistant Enterobacteriaceae, ticarcillin-YTR 830 and ticarcillin-clavulanate were synergistic against 90% of strains; for ticarcillin-sulbactam, 70% showed synergy. The synergistic activity of all three inhibitors was similar against strains resistant only to ticarcillin; for strains resistant to all four extended-spectrum penicillins, the activity of ticarcillin with YTR 830 and clavulanate was similar (synergy against 79% of strains) and superior to ticarcillin-sulbactam (synergy against 39% of strains). YTR 830 was more active than clavulanate against Serratia, Citrobacter, Proteus and Providencia spp. Piperacillin, mezlocillin and apalcillin susceptible strains, with MICs of 8-16 mg/l, showed synergy with inhibitors against 37-87% of strains. Amongst pseudomonads, no synergy was demonstrated against Pseudomonas aeruginosa; ticarcillin produced synergy with the inhibitors against Ps. maltophilia, while piperacillin-YTR 830 and apalcillin-YTR 830 were synergistic against Ps. cepacia. YTR 830 appears to have comparable in-vitro activity to that of clavulanate, and further development of this compound is warranted.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Ampicillin,
http://linkedlifedata.com/resource/pubmed/chemical/Clavulanic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Clavulanic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Mezlocillin,
http://linkedlifedata.com/resource/pubmed/chemical/Penicillanic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Penicillins,
http://linkedlifedata.com/resource/pubmed/chemical/Piperacillin,
http://linkedlifedata.com/resource/pubmed/chemical/Sulbactam,
http://linkedlifedata.com/resource/pubmed/chemical/Ticarcillin,
http://linkedlifedata.com/resource/pubmed/chemical/apalcillin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0305-7453
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
18
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
177-84
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3019984-Ampicillin,
pubmed-meshheading:3019984-Clavulanic Acid,
pubmed-meshheading:3019984-Clavulanic Acids,
pubmed-meshheading:3019984-Drug Synergism,
pubmed-meshheading:3019984-Enterobacteriaceae,
pubmed-meshheading:3019984-Mezlocillin,
pubmed-meshheading:3019984-Penicillanic Acid,
pubmed-meshheading:3019984-Penicillins,
pubmed-meshheading:3019984-Piperacillin,
pubmed-meshheading:3019984-Pseudomonas,
pubmed-meshheading:3019984-Sulbactam,
pubmed-meshheading:3019984-Ticarcillin
|
pubmed:year |
1986
|
pubmed:articleTitle |
Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|